What is InDevR?
Based in Boulder, CO, InDevR is a biotechnology company making significant strides in vaccine process optimization and manufacturing through its advanced protein characterization tools. The company has a proven track record with several successful life science tool product lines that support vaccine development and serological research. InDevR also extends its expertise to biotherapeutic companies through testing and custom services, demonstrating a comprehensive approach to supporting the broader life sciences ecosystem. Its venture-backed status, including funding from Adjuvant Capital and the Bill & Melinda Gates Foundation, highlights its potential and the confidence investors place in its technological contributions.
How much funding has InDevR raised?
InDevR has raised a total of $19.3M across 4 funding rounds:
Grant
$2.9M
Series A
$7M
Debt
$350K
Series B
$9M
Grant (2014): $2.9M with participation from National Institute of Allergy and Infectious Diseases
Series A (2019): $7M led by Adjuvant Capital
Debt (2020): $350K supported by PPP
Series B (2023): $9M featuring Adjuvant Capital and BioMérieux Turkey
Key Investors in InDevR
Adjuvant Capital
Adjuvant Capital is a venture capital firm focused on financing innovative life science technologies that address high-burden public health challenges. The company invests in areas such as infectious diseases, maternal and child health, and nutrition, aiming to make impactful medical innovations accessible to underserved populations.
National Institute of Allergy and Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID) is part of the U.S. Department of Health and Human Services and is a leading supporter of basic and applied research to understand, treat, and prevent infectious, immunologic, and allergic diseases. Their funding often supports groundbreaking research and development in the life sciences.
BioMérieux Turkey
BioMérieux is a global leader in the field of in vitro diagnostics, providing innovative solutions for clinical diagnostics and industrial microbiology. Their involvement suggests a strategic interest in InDevR's technology for diagnostic or manufacturing applications within the broader healthcare and biotechnology sectors.
What's next for InDevR?
The recent major strategic investment in InDevR signals a pivotal phase for the company, likely focused on scaling its manufacturing capabilities, expanding its market reach, and further developing its proprietary protein characterization technologies. As a venture-backed entity operating within the critical field of vaccine development and optimization, InDevR is poised to leverage this capital to enhance its product offerings and solidify its position as a key player in the biotechnology tools market. Future growth will likely involve strategic partnerships and continued innovation to address evolving needs in biopharmaceutical production and infectious disease research.
See full InDevR company page
